Trial Profile
Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Tigilanol tiglate (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors QBiotics
- 31 May 2023 According to a QBiotics Group Limited media release, the safety and efficacy data from this study will be presented at the Sachs 9th Annual Immuno-Oncology Innovation Forum and the BIO International Convention, both being held in the US through June 2023, by Richard Godfrey.
- 12 Aug 2020 Results published in the QBiotics Media Release
- 09 Dec 2019 According to a QBiotics media release, results from this trial have been published in the journal EBioMedicine (a peer-reviewed research journal by The Lancet.)